SYNLOGIC, INC. Financing Cash Flow
SYNLOGIC, INC. (SYBX) reported Financing Cash Flow of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-03-12
- SYNLOGIC, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- SYNLOGIC, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- SYNLOGIC, INC. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- SYNLOGIC, INC. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- SYNLOGIC, INC. net cash provided by (used in) financing activities for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- SYNLOGIC, INC. net cash provided by (used in) financing activities for fiscal 2024 was $172.00K, a 99.18% decline from fiscal 2023.
- SYNLOGIC, INC. net cash provided by (used in) financing activities for fiscal 2023 was $20.94M.
- SYNLOGIC, INC. net cash provided by (used in) financing activities for fiscal 2022 was -$2.04M, a 102.28% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $9.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $9.00K derived: sum of 3 quarters · filed 2026-03-12 | $8.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $9.00K derived: sum of 2 quarters · filed 2026-03-12 | $8.00K derived: sum of 3 quarters · filed 2026-03-12 | $156.00K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $8.00K derived: sum of 2 quarters · filed 2026-03-12 | $156.00K derived: sum of 3 quarters · filed 2026-03-12 | $172.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $147.00K derived: sum of 2 quarters · filed 2025-11-13 | $163.00K 10-Q · filed 2025-11-13 | $19.74M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $148.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $164.00K 10-Q · filed 2025-08-07 | $163.00K 10-Q · filed 2024-08-08 | $19.74M derived: sum of 3 quarters · filed 2025-08-07 | $19.81M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $16.00K 10-Q · filed 2025-05-08 | $19.60M derived: sum of 2 quarters · filed 2025-05-08 | $19.66M derived: sum of 3 quarters · filed 2025-05-08 | $20.05M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $19.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $19.64M derived: sum of 2 quarters · filed 2025-03-06 | $20.03M derived: sum of 3 quarters · filed 2025-03-06 | $20.94M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $451.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.36M 10-Q · filed 2024-11-12 | -$865.00K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $389.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.30M 10-Q · filed 2024-08-08 | -$927.00K derived: sum of 3 quarters · filed 2024-08-08 | -$876.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $913.00K 10-Q · filed 2024-05-14 | -$1.32M derived: sum of 2 quarters · filed 2024-05-14 | -$1.26M derived: sum of 3 quarters · filed 2024-05-14 | -$1.26M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$2.18M derived: sum of 2 quarters · filed 2024-03-19 | -$2.17M derived: sum of 3 quarters · filed 2024-03-19 | -$2.04M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $51.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $57.00K derived: sum of 2 quarters · filed 2023-11-09 | $189.00K 10-Q · filed 2023-11-09 | $69.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $138.00K 10-Q · filed 2023-08-10 | $18.00K derived: sum of 3 quarters · filed 2023-08-10 | $48.87M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $132.00K 10-Q · filed 2023-05-11 | $12.00K derived: sum of 2 quarters · filed 2023-05-11 | $48.87M derived: sum of 3 quarters · filed 2023-05-11 | $81.50M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $48.73M derived: sum of 2 quarters · filed 2023-03-29 | $81.36M derived: sum of 3 quarters · filed 2023-03-29 | $89.38M 10-K · filed 2023-03-29 | |
| 2021-09-30 | $48.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $81.48M derived: sum of 2 quarters · filed 2022-11-10 | $89.50M 10-Q · filed 2022-11-10 | $97.97M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $32.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $40.65M 10-Q · filed 2022-08-11 | $49.12M derived: sum of 3 quarters · filed 2022-08-11 | $50.33M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $8.02M 10-Q · filed 2022-05-12 | $16.49M derived: sum of 2 quarters · filed 2022-05-12 | $17.70M derived: sum of 3 quarters · filed 2022-05-12 | $21.48M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $9.68M derived: sum of 2 quarters · filed 2022-03-17 | $13.46M derived: sum of 3 quarters · filed 2022-03-17 | $13.39M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $4.99M derived: sum of 2 quarters · filed 2021-11-10 | $4.92M 10-Q · filed 2021-11-10 | $4.85M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $3.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $3.72M 10-Q · filed 2021-08-12 | $3.65M derived: sum of 3 quarters · filed 2021-08-12 | $3.60M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$69.00K 10-Q · filed 2021-05-13 | -$138.00K derived: sum of 2 quarters · filed 2021-05-13 | -$191.00K derived: sum of 3 quarters · filed 2021-05-13 | $79.60M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | -$69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$122.00K derived: sum of 2 quarters · filed 2021-03-25 | $79.67M derived: sum of 3 quarters · filed 2021-03-25 | $79.60M 10-K · filed 2021-03-25 | |
| 2019-09-30 | -$53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $79.74M derived: sum of 2 quarters · filed 2020-11-05 | $79.67M 10-Q · filed 2020-11-05 | $79.72M derived: sum of 4 quarters · filed 2020-11-05 | |
| 2019-06-30 | $79.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $79.73M 10-Q · filed 2020-08-06 | $79.77M derived: sum of 3 quarters · filed 2020-08-06 | $79.76M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | -$65.00K 10-Q · filed 2020-05-08 | -$21.00K derived: sum of 2 quarters · filed 2020-05-08 | -$31.00K derived: sum of 3 quarters · filed 2020-05-08 | $28.77M derived: sum of 4 quarters · filed 2020-05-08 | |
| 2018-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $34.00K derived: sum of 2 quarters · filed 2020-03-12 | $28.84M derived: sum of 3 quarters · filed 2020-03-12 | $82.48M 10-K · filed 2020-03-12 | |
| 2018-09-30 | -$10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $28.80M derived: sum of 2 quarters · filed 2019-11-12 | $82.44M 10-Q · filed 2019-11-12 | $82.21M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | $28.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $82.45M 10-Q · filed 2019-08-08 | $82.22M derived: sum of 3 quarters · filed 2019-08-08 | $81.93M derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | $53.64M 10-Q · filed 2019-05-09 | $53.42M derived: sum of 2 quarters · filed 2019-05-09 | $53.12M derived: sum of 3 quarters · filed 2019-05-09 | $120.30M derived: sum of 4 quarters · filed 2019-05-09 | |
| 2017-12-31 | -$227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$521.00K derived: sum of 2 quarters · filed 2019-03-12 | $66.65M derived: sum of 3 quarters · filed 2019-03-12 | $66.68M 10-K · filed 2019-03-12 | |
| 2017-09-30 | -$294.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $66.88M derived: sum of 2 quarters · filed 2018-11-13 | $66.91M 10-Q · filed 2018-11-13 | ||
| 2017-06-30 | $67.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $67.20M 10-Q · filed 2018-08-09 | $25.00K 10-Q · filed 2017-08-04 | ||
| 2017-03-31 | $25.00K 10-Q · filed 2017-05-09 | ||||
| 2016-09-30 | $30.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $30.89M derived: sum of 2 quarters · filed 2017-11-13 | $30.89M 10-Q · filed 2017-11-13 | ||
| 2016-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $9.00K 10-Q · filed 2017-08-04 | |||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |